D. Macdonald

发表

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Susan M. Chang, T. Mikkelsen, M. Gilbert, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group

Patrick Y Wen, Susan M. Chang, Michael A Vogelbaum, 2012, Neurosurgery.

Response criteria for phase II studies of supratentorial malignant glioma.

T. Cascino, J. Cairncross, D. Macdonald, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

L Junck, Susan M. Chang, P. Wen, 2011, The Lancet. Oncology.

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

D. Louis, J. Cairncross, D. Finkelstein, 1998, Journal of the National Cancer Institute.

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.

Susan M. Chang, M. Gilbert, D. Sargent, 2012, The Lancet. Oncology.

Apparent transverse relaxation ( R2∗ ) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma

Ravi S. Menon, R. Menon, G. Bauman, 2018, Journal of medical imaging and radiation oncology.

Low Grade Glioma: A Measuring Radiographic Response to Radiotherapy

B. Fisher, G. Bauman, D. Macdonald, 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Response assessment criteria for brain metastases: proposal from the RANO group.

Martin Bendszus, Riccardo Soffietti, Susan M. Chang, 2015, The Lancet. Oncology.

Successful chemotherapy for newly diagnosed aggressive oligodendroglioma

J. Cairncross, L. Gaspar, J. Cairncross, 1990, Annals of neurology.

Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

S. Rosenfeld, D. Macdonald, D. Ramsay, 2000, Neuro-oncology.

Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma

J. Cairncross, D. Macdonald, N. Vick, 1999, Neurology.

Salvage chemotherapy for oligodendroglioma.

J. Cairncross, D. Macdonald, P. Forsyth, 1996, Journal of neurosurgery.

Salvage chemotherapy for oligodendroglioma.

J. Cairncross, D. Macdonald, P. Forsyth, 1996 .

Pre-radiation Chemotherapy for Malignant Glioma in Adults

B. Fisher, L. Gaspar, D. Macdonald, 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Adjuvant chemotherapy for brain tumor

D. Macdonald, 1991 .

Chemotherapy for oligodendroglioma. Progress report.

J. Cairncross, D. Macdonald, 1991, Archives of Neurology.

Oligodendroglioma: a new chemosensitive tumor.

J. Cairncross, D. Macdonald, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New frontiers in the treatment of malignant glioma.

D. Macdonald, 2003, Seminars in oncology.

A phase III randomized prospective trial of external beam radiotherapy (ERT), mitomycin C (MITO), BCNU, and 6-mercaptopurine (6-MP) for the treatment of adults with anaplastic glioma of the brain

A. Friedman, S. Rosenfeld, L. Gaspar, 1994 .

Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma

K. Aldape, M. Mehta, B. Fisher, 2021, JCO precision oncology.

Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience

B. Fisher, G. Bauman, D. Macdonald, 2012, Journal of Neuro-Oncology.

A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma

K. Bélanger, S. Ludwin, E. Eisenhauer, 2003, Investigational New Drugs.

Temozolomide for recurrent high-grade glioma.

D. Macdonald, 2001, Seminars in oncology.

3D Conformal Radiotherapy and Cisplatin for Recurrent Malignant Glioma

B. Fisher, G. Bauman, D. Macdonald, 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424

B. Fisher, D. D'Souza, D. Macdonald, 2020 .

Bihemispheric malignant glioma: One size does not fit all

B. Fisher, J. Cairncross, G. Bauman, 1998, Journal of Neuro-Oncology.

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).

K. Bélanger, L. Seymour, D. Macdonald, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.

K. Cornetta, V. Mathews, D. Williams, 1998, Medical and pediatric oncology.

Primary cerebral fibrosarcomas. Clinicopathologic study and review of the literature

J. Cairncross, D. Macdonald, J. Kaufmann, 1993, Cancer.

Clinicopathologic Study and Review of the Literature

J. Cairncross, L. Gaspar, D. Macdonald, 1993 .

Primary diffuse leptomeningeal oligodendroglioma. Case report.

D. Macdonald, D. Ramsay, R. Chen, 1995, Journal of neurosurgery.

Ki-67: a prognostic factor for low-grade glioma?

B. Fisher, J. Cairncross, L. Stitt, 2002, International journal of radiation oncology, biology, physics.

Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study

J. Cairncross, E. Eisenhauer, D. Macdonald, 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Primary leptomeningeal lymphoma

B. O'neill, D. Macdonald, J. Posner, 1991, Neurology.

Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma

B. Fisher, Ting-Yim Lee, E. Wong, 2014, Journal of medical radiation sciences.

A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424.

D. Brachman, M. Mehta, B. Fisher, 2013 .

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

K. Hoang-Xuan, M. J. van den Bent, M. Taphoorn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.

L. Deangelis, J. Cairncross, S. Rosenfeld, 2006, Neuro-oncology.

High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma

L. Deangelis, J. Cairncross, S. Rosenfeld, 2003, Journal of Neuro-Oncology.

Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

S. Rosenfeld, D. Macdonald, D. Ramsay, 2000, Neuro-oncology.

Ataxia and Diplopia in a Patient with Chronic Lymphocytic Leukemia

Donald H. Lee, D. Macdonald, M. Tartaglia, 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Low-grade gliomas in children: tumor volume response to radiation.

B. Fisher, J. Cairncross, L. Stitt, 1998, Journal of neurosurgery.

Phase II study of topotecan in patients with recurrent malignant glioma

E. Eisenhauer, D. Macdonald, C. Sawka, 1996 .

The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma

W. Mason, K. Bélanger, D. Macdonald, 2008 .

Neurologic complications of chemotherapy.

D. Macdonald, 1991, Neurologic clinics.

Cerebellar liponeurocytoma: a rare intracranial tumor with possible familial predisposition. Case report.

D. Macdonald, D. Ramsay, Michael D. Staudt, 2016, Journal of neurosurgery.

Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.

L. Recht, T. Mikkelsen, M. Weller, 2015 .

Absence of hereditary mutations in exons 5 through 9 of the p53 gene and exon 24 of the neurofibromin gene in families with glioma

J. Cairncross, J. Cairncross, D. Macdonald, 1994, Annals of neurology.

Cognitive functioning in long-term survivors of high-grade glioma.

Y. Archibald, B. Fisher, J. Cairncross, 1994, Journal of neurosurgery.

Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

W. Mason, K. Bélanger, D. Eisenstat, 2011, Current oncology.

Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma.

J. Cairncross, D. Macdonald, D. Lee, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.

W. Mason, D. Macdonald, L. Abrey, 2002, Journal of neurosurgery.

Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.

B. Fisher, D. Macdonald, W. Roa, 2002, International journal of radiation oncology, biology, physics.

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

W. Mason, K. Bélanger, D. Eisenstat, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do epileptic seizures predict outcome in patients with oligodendroglioma?

Donald H. Lee, J. Cairncross, D. Macdonald, 2011, Epilepsy Research.

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

R A Betensky, D. Louis, A. Stemmer-Rachamimov, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

R. Mirimanoff, R. Stupp, W. Mason, 2011, Neurology.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

K. Aldape, M. Mehta, B. Fisher, 2018, JAMA oncology.

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

P. Wen, L. Deangelis, M. J. van den Bent, 2017, Neuro-oncology.

Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment.

B. Fisher, J. Cairncross, L. Gaspar, 1992, International journal of radiation oncology, biology, physics.

Loss of Heterozygosity Analysis of Chromosomes 9, 10 and 17 in Gliomas in Families

J. Cairncross, D. Macdonald, D. Ramsay, 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Clinical trial end points for high-grade glioma: the evolving landscape.

Timothy F Cloughesy, Mark R Gilbert, Wolfgang Wick, 2011, Neuro-oncology.

Gliomas in Families

W. Cavenee, D. Macdonald, D. Ramsay, 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

T. Cascino, J. Buckner, D. Macdonald, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of PX-866 in recurrent glioblastoma.

W. Mason, E. Eisenhauer, S. Banerji, 2012, Neuro-oncology.

Canadian recommendations for the treatment of glioblastoma multiforme

W. Mason, D. Eisenstat, D. Macdonald, 2007, Current oncology.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

M Brada, K. Hoang-Xuan, R. Stupp, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Response Assessment in Neuro-Oncology Clinical Trials.

Susan M. Chang, P. Wen, M. J. van den Bent, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Patrick Y Wen, Susan M. Chang, Michael A Vogelbaum, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis.

B. Fisher, J. Cairncross, L. Stitt, 1999, International journal of radiation oncology, biology, physics.

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

G S Bauman, D. Louis, B. Fisher, 2000, International journal of radiation oncology, biology, physics.

Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131

D. Brachman, M. Mehta, M. Vogelbaum, 2015, Journal of Neuro-Oncology.

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.

J. Herman, P. Brown, M. Mehta, 2009, Neuro-oncology.

Syncope from head and neck cancer

E. Strong, D. Macdonald, J. Posner, 2004, Journal of Neuro-Oncology.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Eudocia Q Lee, Martin Bendszus, Gordon J Harris, 2018, The Lancet. Oncology.

PCV for Oligodendroglial Tumors: In Search of Prognostic Factors for Response and Survival

J. Cairncross, L. Stitt, D. Macdonald, 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Successful chemotherapy for recurrent malignant oligodendroglioma

J. Cairncross, D. Macdonald, 1988, Annals of neurology.

Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

M. Delorenzi, L. Mariani, R. Stupp, 2013, Acta Neuropathologica.

Selection bias, survival, and brachytherapy for glioma.

P. Gutin, J. Cairncross, M. Bernstein, 1992, Journal of neurosurgery.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

M. Mehta, P. Wen, L. Deangelis, 2014, Neuro-oncology.

Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation.

B. Fisher, L. Stitt, G. Bauman, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

L. Recht, T. Mikkelsen, M. Weller, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

D. Louis, J. Cairncross, A. Stemmer-Rachamimov, 2000, Journal of neurosurgery.

Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma.

J. Cairncross, D. Macdonald, M J Winger, 1989, Journal of neurosurgery.

Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.

S. Coons, D. Brachman, M. Mehta, 2015, International journal of radiation oncology, biology, physics.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

Dynamic perfusion CT in brain tumors.

Ting-Yim Lee, G. Bauman, D. Macdonald, 2015, European journal of radiology.

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain

Allan H. Friedman, Gunilla C. Bentel, J. Gregory Cairncross, 1996 .

Survey of treatment recommendations for anaplastic oligodendroglioma.

D. Louis, L. Deangelis, W. Mason, 2007, Neuro-oncology.

Low-grade gliomas in children: tumor volume response to radiation.

B. Fisher, J. Cairncross, L. Stitt, 1998, Neurosurgical focus.

Selection bias in clinical trails of anaplastic glioma

J. Cairncross, D. Macdonald, S. Schold, 1989, Annals of neurology.

Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas.

B. Fisher, L. Stitt, D. Macdonald, 2001, International journal of radiation oncology, biology, physics.

Three major histological types of diffuse infiltrative tumors are recognized by the World Health Organization’s classification of gliomas: astrocytomas, oligodendrogliomas and oligo-

J. Cairncross, L. Stitt, D. Macdonald, 2002 .

Metastatic anaplastic oligodendroglioma

J. Cairncross, D. Macdonald, J. Gilbert, 1989, Neurology.

Neurocytomas: long-term experience of a single institution.

G. Bauman, D. Macdonald, K. Tay, 2011, Neuro-oncology.

New therapies of primary CNS lymphomas and oligodendrogliomas

D. Macdonald, 2005, Journal of Neuro-Oncology.

A PHASE III RANDOMIZED PROSPECTIVE TRIAL OF EXTERNAL BEAM RADKlTHERAPY, MITOMYCIN C, CARMUSTINE, AND 6-~RCA~~NE FOR THE TREATMENT OF ADULTS WITH ANAPLAS'IK GLIOMA OF THE BRAIN

A. Friedman, J. Cairncross, S. Rosenfeld, 1995 .

Adult supratentorial low-grade glioma: long-term experience at a single institution.

B. Fisher, J. Cairncross, G. Bauman, 2009, International journal of radiation oncology, biology, physics.

Steroid‐induced CT changes in patients with recurrent malignant glioma

J. Cairncross, D. Macdonald, J. H. Warwick Pexman, 1988, Neurology.

A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme.

J. Cairncross, L. Gaspar, G. Bauman, 1994, International journal of radiation oncology, biology, physics.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Susan M. Chang, P. Brown, M. Mehta, 2018, The Lancet. Oncology.

Radiotherapy for Pediatric Central Nervous System Tumors: A Regional Cancer Centre Experience

B. Fisher, L. Stitt, G. Bauman, 2004, Journal of Neuro-Oncology.

Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

E C Halperin, D. Bigner, J. Cairncross, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.

E. Eisenhauer, D. Macdonald, C. Sawka, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424.

M. Mehta, B. Fisher, D. D'Souza, 2020, International journal of radiation oncology, biology, physics.

Detecting tumor progression in glioma: current standards and new techniques

G. Bauman, D. Macdonald, J. Belliveau, 2016, Expert review of anticancer therapy.

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

T. Cloughesy, O. Chinot, D. Macdonald, 2013, Current Neurology and Neuroscience Reports.

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study

W. Mason, D. Macdonald, L. McIntosh, 2012, Investigational New Drugs.

Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma.

Susan M. Chang, P. Wen, M. J. van den Bent, 2015, Neuro-oncology practice.

Medulloblastomas in late middle age and the elderly: report of 2 cases.

D. Macdonald, D. Ramsay, J. Bonnin, 1995, Clinical neuropathology.

Phase II study of tiazofurin in gliomas in adults

J. Cairncross, E. Eisenhauer, D. Macdonald, 1993, Journal of Neuro-Oncology.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group

Susan M. Chang, P. Wen, L. Deangelis, 2018, Neuro-oncology.

Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.

J. Olson, M. Prados, A. Yung, 2005, Cancer investigation.

Interferon-alfa in the Treatment of Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer Bevacizumab for the Treatment of Patients with Glioblastoma Multiforme That Has Relapsed or Progressed Following Prior Therapy

D. Macdonald, J. Perry, 2014 .

The dose–volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection

B. Fisher, J. Cairncross, L. Stitt, 2007, Journal of Neuro-Oncology.

Benefit of Temozolomide Compared to Procarbazine in Treatment of Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Performance Status, and Health Related Quality of Life

J. Olson, M. Prados, A. Yung, 2005 .

Measuring Bias in Uncontrolled Brain Tumor Trials – to Randomize or Not to Randomize?

J. Cairncross, D. Macdonald, W. Irish, 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Evaluating glioma therapies: modeling treatments and predicting outcomes.

D. Macdonald, W. Irish, M. Brothers, 1995, Journal of the National Cancer Institute.

Operative Complications with and without Image Guidance: A Systematic Review and Meta-Analysis of the Ommaya Reservoir Literature.

Thomas Walker, D. Macdonald, J. Megyesi, 2019, World neurosurgery.

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.

E C Halperin, G C Bentel, L Gaspar, 1996, International journal of radiation oncology, biology, physics.

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.

M. Dimopoulos, C. Buske, D. Macdonald, 2019, Journal of Clinical Oncology.

In response to Drs. Mehrkens, Stummer, and Kreth

G. Bauman, D. Macdonald, G. Cairncross, 2000 .

Malignant glioma--timing of response to radiation therapy.

J. Cairncross, L. Gaspar, D. Macdonald, 1993, International journal of radiation oncology, biology, physics.

Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases

W. Mason, D. Macdonald, S. Climans, 2020, BMJ Case Reports.

ET-12PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

L. Recht, T. Mikkelsen, M. Weller, 2014 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Low-grade gliomas, mixed gliomas, and oligodendrogliomas.

D. Macdonald, 1994, Seminars in oncology.

Surgery for single brain metastasis.

J. Cairncross, D. Macdonald, 1990, The New England journal of medicine.

Image-guided Ommaya reservoir insertion for intraventricular chemotherapy: a retrospective series

D. Macdonald, J. Megyesi, J. Lau, 2018, Acta Neurochirurgica.

Survey of treatment recommendations for anaplastic oligodendroglioma.

D. Louis, L. Deangelis, W. Mason, 2007, Neuro-oncology.

Response assessment criteria for brain metastases: proposal from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2015, The Lancet. Oncology.

Image-guided Ommaya reservoir insertion for intraventricular chemotherapy: a retrospective series

Jonathan C. Lau, D. Macdonald, J. Megyesi, 2018, Acta Neurochirurgica.